Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.

Neurokinin 1 receptor (NK1R) agonist mediated protection of the eye is described. The protection can reduce dry eye and ocular infections, particularly in individuals with reduced NK1R activity.

A noxipoint stimulating device uses light, mechanical force, and heat as a source of stimulating energy, which is configured to be applied on the Noxipoints.

The present invention relates to: a combination therapy and a combination product that are for the mobilization of a large amount of hematopoietic stem cells in blood and include substance-P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting a large amount of mobilized hematopoietic stem cells, the method comprising a step for isolating a blood fraction containing the mobilized hematopoietic stem cells from peripheral blood obtained from an individual sequentially administered with substance P and AMD3100 or a pharmaceutically acceptable salt thereof; and a use of a combined product containing substance P and AMD3100 or a pharmaceutically acceptable salt thereof for the mobilization of a large amount of hematopoietic stem cells in blood.

The present invention relates to: a combination therapy and a combination product that are for the mobilization of a large amount of hematopoietic stem cells in blood and include substance-P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting a large amount of mobilized hematopoietic stem cells, the method comprising a step for isolating a blood fraction containing the mobilized hematopoietic stem cells from peripheral blood obtained from an individual sequentially administered with substance P and AMD3100 or a pharmaceutically acceptable salt thereof; and a use of a combined product containing substance P and AMD3100 or a pharmaceutically acceptable salt thereof for the mobilization of a large amount of hematopoietic stem cells in blood.

Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N.sup.6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5′-O-(glycine-N-carbonyl-N.sup.6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5-deoxy-5′-(glycine-N-amido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

A compound for treatment of pain comprising a single multivalent/multifunctional ligand with agonist activity at opioid receptors and with antagonist activity at NK-1 receptors, joined by a linker. Also disclosed is a pharmaceutical compound comprising the above compound in a pharmaceutically acceptable carrier.

Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N.sup.6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5-glycylcarbonyl-N.sup.6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5-deoxy-5-(N-glycylureido)-N.sup.6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.